Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020

SELL
$1.69 - $3.88 $144,939 - $332,760
-85,763 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.73 - $2.42 $148,369 - $207,546
85,763 New
85,763 $189,000

Others Institutions Holding NYMX

About NYMOX PHARMACEUTICAL CORP


  • Ticker NYMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,265,000
  • Market Cap $42.9M
  • Description
  • Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...
More about NYMX
Track This Portfolio

Track 683 Capital Management, LLC Portfolio

Follow 683 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.